Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.

Humanigen to Host Investor KOL Conference Call

Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil

REMINDER: Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020

Humanigen Appoints Bob Atwill as Head of Asia-Pacific Region

Humanigen to Present at the BTIG Virtual Biotechnology Conference 2020

Humanigen to Host Investor Conference Call to Discuss NIH’s Selection of Lenzilumab for Big Effect Trial

Timothy Morris Joins Humanigen as Chief Operating Officer and Chief Financial Officer

The study will measure how the combination of lenzilumab and remdesivir fares  compared to remdesivir alone.

Humanigen Stock Up 13% After NIH Picks Its Drug for a COVID-19 Study

News for Humanigen Stock (HGEN)